Successful gene therapy for β-thalassemia requires optimal numbers of autologous gene-transduced hematopoietic stem and progenitor cells (HSPCs) with high repopulating capacity. Previous studies suggested superior mobilization in these patients by the combination of granulocyte–colony stimulating factor (G-CSF) plus plerixafor over single agents. We mobilized four adult patients using G-CSF+plerixafor to assess the intra-individual variation of the circulating CD34+ cells number and subtypes preand post-plerixafor administration. The procedure was well-tolerated and the target cell dose of ≥8.106 CD34+ cells/kg was achieved in three of them with one apheresis procedure. The addition of plerixafor unanimously increased the number of circulating CD34+ cells, and the frequency of the most primitive CD34+ subtypes: CD34+/38- and CD34+/133+/38- as well as the in vitro clonogenic potency. Microarray analyses of CD34+ cells purified from the leukapheresis of one patient mobilized twice, with G-CSF and with G-CSF+plerixafor, highlighted in G-CSF+plerixafor-mobilized CD34+ cells, higher levels of expression genes involved in HSPC motility, homing, and cell cycles. In conclusion, G-CSF+plerixafor in β-thalassemia patients mobilizes optimal numbers of HSPCs with characteristics that suggest high capacity of engraftment after transplantation.

Elena, B., Rita, B., Contino, F., Rosalia Di Stefano, ., Anna, M., Aldo, F., et al. (2017). Granulocyte–colony stimulating factor plus plerixafor inpatients with –thalassemia major results in the effective mobilization of primitiveCD34+ cells with specific gene expression profile. THALASSEMIA REPORTS, 7(7), 11-17 [doi:10.4081/thal.2017.6392].

Granulocyte–colony stimulating factor plus plerixafor inpatients with –thalassemia major results in the effective mobilization of primitiveCD34+ cells with specific gene expression profile

CONTINO, Flavia;FEO, Salvatore;
2017-01-01

Abstract

Successful gene therapy for β-thalassemia requires optimal numbers of autologous gene-transduced hematopoietic stem and progenitor cells (HSPCs) with high repopulating capacity. Previous studies suggested superior mobilization in these patients by the combination of granulocyte–colony stimulating factor (G-CSF) plus plerixafor over single agents. We mobilized four adult patients using G-CSF+plerixafor to assess the intra-individual variation of the circulating CD34+ cells number and subtypes preand post-plerixafor administration. The procedure was well-tolerated and the target cell dose of ≥8.106 CD34+ cells/kg was achieved in three of them with one apheresis procedure. The addition of plerixafor unanimously increased the number of circulating CD34+ cells, and the frequency of the most primitive CD34+ subtypes: CD34+/38- and CD34+/133+/38- as well as the in vitro clonogenic potency. Microarray analyses of CD34+ cells purified from the leukapheresis of one patient mobilized twice, with G-CSF and with G-CSF+plerixafor, highlighted in G-CSF+plerixafor-mobilized CD34+ cells, higher levels of expression genes involved in HSPC motility, homing, and cell cycles. In conclusion, G-CSF+plerixafor in β-thalassemia patients mobilizes optimal numbers of HSPCs with characteristics that suggest high capacity of engraftment after transplantation.
2017
Elena, B., Rita, B., Contino, F., Rosalia Di Stefano, ., Anna, M., Aldo, F., et al. (2017). Granulocyte–colony stimulating factor plus plerixafor inpatients with –thalassemia major results in the effective mobilization of primitiveCD34+ cells with specific gene expression profile. THALASSEMIA REPORTS, 7(7), 11-17 [doi:10.4081/thal.2017.6392].
File in questo prodotto:
File Dimensione Formato  
Thal-Rep_2017.pdf

accesso aperto

Descrizione: Articolo principale e supplementi
Dimensione 1.19 MB
Formato Adobe PDF
1.19 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/236558
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact